お知らせ • Jul 02
Quest PharmaTech Inc., Annual General Meeting, Aug 25, 2025 Quest PharmaTech Inc., Annual General Meeting, Aug 25, 2025. Location: alberta, edmonton Canada New Risk • Sep 27
New major risk - Revenue and earnings growth Earnings have declined by 40% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (76% average weekly change). Earnings have declined by 40% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (CA$4.23m market cap, or US$3.13m). お知らせ • Aug 13
Quest PharmaTech Inc., Annual General Meeting, Oct 08, 2024 Quest PharmaTech Inc., Annual General Meeting, Oct 08, 2024. Location: hybrid meeting, Canada お知らせ • May 31
Quest Pharmatech Inc. Announces the Appointment of Bradley J. Glass to the Board of Directors Quest PharmaTech Inc. announced the appointment of Mr. Bradley J. Glass to the Board of Directors, subject to regulatory approval. Mr. Glass has served as the General Counsel of Hepalink USA Inc. and its subsidiaries ("Hepalink") for the past two years. In that role, Mr. Glass is responsible for managing all of Hepalink's U.S. legal issues, including matters involving contracts, employment, intellectual property, litigation, tax, insurance, regulatory compliance, and permitting. Prior to joining Hepalink, Mr. Glass was in private law practice for over twenty years and advised, counseled, and represented clients all over the United States on a broad range of matters. Mr. Glass has represented and litigated numerous matters in federal, state, and local courts and administrative tribunals on a wide range of sophisticated regulatory and business matters. Board Change • Apr 01
Less than half of directors are independent There are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. 1 experienced director. 4 highly experienced directors. 2 independent directors (4 non-independent directors). CEO & Director Madi Madiyalakan is the most experienced director on the board, commencing their role in 2004. Independent Director John Lievonen was the last independent director to join the board, commencing their role in 2021. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors. お知らせ • Jan 24
Quest PharmaTech Inc. Receives Recommendations from the Data Safety Monitoring Board to Discontinue Oregovomab Phase III Clinical Study Quest PharmaTech Inc. announced that it has received information that the Phase III clinical trial of oregovomab for the treatment of Ovarian Cancer, sponsored by CanariaBio Inc. ("CAB"), has received recommendations from the Data Safety Monitoring Board (DSMB), an independent committee appointed by CAB to advise on the trials, to discontinue the clinical trial after conducting a futility evaluation for interim progression free survival in study subjects. The DSMB also expressed the opinion that due to the characteristics of immunotherapy drugs, there is a possibility of significant efficacy in overall survival and recommended that follow up observations be continued in study subjects. Quest holds bonds of Korea-based OQP Bio Inc. (the "OQP Bonds") received in connection with the sale of the immunotherapy technology assets, including oregovomab, of investee company OncoQuest Inc. in April 2020. Quest continues to pursue the monetization of the OQP Bonds and is currently engaged in discussions with CanariaBio M Co. Ltd. ("CABM"), the parent company of OQP Bio as well as KOSDAQ listed CAB. The OQP Bonds are currently illiquid and there can be no assurance that the Company will be successful in negotiating monetization terms with CABM for its OQP Bio bonds, that any definitive agreement will be entered into for such monetization, or that the Company will ultimately be able to monetize all or any part of its bonds. Quest is also in discussions with CABM on options available for Quest to continue to support the oregovomab clinical program. 